Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | USP14 | P54578 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6621315 | 0.88 | HTR2A (0.41) | HTR2AHTR2CHTR7HTR6OPRM1 | |
| Fluorobenzene SCHEMBL27514554 | 0.86 | USP14 (0.39) | OPRM1TMEM97DRD2DRD4GRM2 | |
| SCHEMBL5872415 | 0.79 | HTR2A (0.47) | HTR2AHTR2CHTR7HTR6OPRM1 | |
| Fluorobenzene SCHEMBL27559483 | 0.78 | DRD2 (0.38) | OPRM1TMEM97DRD2DRD4GRM2 | |
| Fluorobenzene SCHEMBL27494422 | 0.78 | DRD2 (0.38) | OPRM1TMEM97DRD2DRD4GRM2 | |
| Fluorobenzene SCHEMBL27559484 | 0.76 | OPRM1 (0.37) | OPRM1TMEM97DRD2DRD4CACNA1G | |
| Fluorobenzene SCHEMBL27514550 | 0.76 | OPRM1 (0.37) | OPRM1TMEM97DRD2DRD4CACNA1G | |
| SCHEMBL5871456 | 0.76 | HTR1A (0.48) | HTR2AHTR2CHTR7HTR6DRD2 | |
| SCHEMBL8567327 | 0.74 | DRD2 (0.43) | DRD2 | |
| SCHEMBL27667941 | 0.73 | GAA (0.50) | OPRM1USP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | HTR2A 143/4885HTR2C 107/4885HTR7 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.